title: Erythroid induction of chronic myelogenous leukemia K562 cells following treatment with a photoproduct derived from the UV-A irradiation of 5-methoxypsoralen.
abstract: Induction of terminal erythroid differentiation can be an efficient strategy to inhibit proliferation of chronic myelogenous leukemia cells. Psoralens, well-known photo-chemotherapeutic agents, were found to be efficient at inducing erythroid differentiation of K562 cells, an in vitro cell line isolated from the pleural effusion of a patient with chronic myelogenous leukemia in blast crisis. The effects of crude pre-irradiated solutions of 5-methoxypsoralen on erythroid differentiation of human leukemic K-562 cells were evaluated. The major photoproduct was characterized and analyzed, and it was found to induce erythroid differentiation of K562 cells and inhibit NF-kappaB/DNA interactions.
authors.affiliation: Department of Pharmaceutical Sciences, University of Padova, Via Marzolo, 5, 35151, Padova, Italy.
authors.forename: Alessia
authors.initials: A
authors.lastname: Salvador
authors.forename: Stefano
authors.initials: S
authors.lastname: Dall'Acqua
authors.forename: Manlio Sutera
authors.initials: MS
authors.lastname: Sardo
authors.forename: Sergio
authors.initials: S
authors.lastname: Caffieri
authors.forename: Daniela
authors.initials: D
authors.lastname: Vedaldi
authors.forename: Francesco
authors.initials: F
authors.lastname: Dall'Acqua
authors.forename: Monica
authors.initials: M
authors.lastname: Borgatti
authors.forename: Cristina
authors.initials: C
authors.lastname: Zuccato
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Bianchi
authors.forename: Roberto
authors.initials: R
authors.lastname: Gambari
mesh_terms: D000078223:5-Methoxypsoralen; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D002454:Cell Differentiation; D041905:Erythroid Cells / Q000166:cytology* / Q000187:drug effects; D006576:Heterocyclic Compounds, 4 or More Rings / Q000737:chemistry* / Q000627:therapeutic use; D006801:Humans; D007536:Isomerism; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D008730:Methoxsalen / Q000031:analogs & derivatives* / Q000737:chemistry / Q000528:radiation effects; D008968:Molecular Conformation; D016328:NF-kappa B / Q000378:metabolism; D010782:Photolysis; D014466:Ultraviolet Rays
chemical_list: D000970:Antineoplastic Agents; D006576:Heterocyclic Compounds, 4 or More Rings; D016328:NF-kappa B; D000078223:5-Methoxypsoralen; D008730:Methoxsalen